1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 50, 12/Dec/2024
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Introduction

Nuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or adenovirus-based COVID-19 vaccine. Although safety from clinical trials was reassuring, small trial populations, low administration rates and limited post-licensure intelligence meant potential rare adverse events were underinformed.

Aim

We aimed to describe Nuvaxovid’s safety profile in a real-world setting.

Methods

We conducted a retrospective observational analysis of adverse events following immunisation (AEFI) spontaneously reported to SAFEVAC, the integrated vaccine safety surveillance system in Victoria and Western Australia. Reports from 14 February 2022 to 30 June 2023 were analysed by vaccinee demographics, reported reactions and COVID-19 vaccine dose, and compared as reporting rates (RR) per 100,000 doses administered.

Results

We received 356 AEFI reports, following 102,946 Nuvaxovid doses administered. Rates were higher after dose 1 than dose 2 (rate ratio: 1.5, p = 0.0008), primary series than booster (rate ratio: 2.4, p < 0.0001), and in females vs males (rate ratio: 1.4, p = 0.004). Clinically confirmed serious AEFI included 94 cases of chest pain (RR = 91.3), two myocarditis (RR = 1.9) and 20 pericarditis (RR = 19.4). Guillain–Barré syndrome or thrombosis with thrombocytopaenia syndromes were not reported, nor deaths attributable to vaccination.

Conclusion

SAFEVAC’s collaborative data model enabled pooling of clinically reviewed data across jurisdictions, increasing the safety profile evidence for Nuvaxovid and improving the odds for identification and description of rare events. This analysis affirmed the safety profile of Nuvaxovid.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.50.2400164
2024-12-12
2024-12-23
/content/10.2807/1560-7917.ES.2024.29.50.2400164
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/50/eurosurv-29-50-3.html?itemId=/content/10.2807/1560-7917.ES.2024.29.50.2400164&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021. Geneva: WHO; 2021. Available from: https://iris.who.int/handle/10665/350881
  2. Australian Government Department of Health and Aged Care. COVID-19 vaccines regulatory status. Canberra: Australian Government. [Accessed: 2 Nov 2023]. Available from: https://www.tga.gov.au/products/covid-19/covid-19-vaccines/covid-19-vaccines-regulatory-status
  3. Australian Government Department of Health and Aged Care (DHAC). COVID-19 vaccine rollout update – 14 February 2022. Canberra: DHAC; 2022 [Available from: https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-14-february-2022?language=en
  4. Feehan J, Apostolopoulos V. Haven't yet been vaccinated for COVID? Novavax might change your mind. Paris: The Conversation; 2022. Available from: https://theconversation.com/havent-yet-been-vaccinated-for-covid-novavax-might-change-your-mind-176694
  5. Attwooll J. How many people were 'waiting for Novavax'? Melbourne: The Royal Australian College of General Practitioners; 2022. Available from: https://www1.racgp.org.au/newsgp/clinical/how-many-people-were-waiting-for-novavax
  6. Dana Daniel. 'Desperately waiting': The Australians who need Novavax for medical reasons. The Sydney Morning Herald; 2022. Available from: https://www.smh.com.au/politics/federal/desperately-waiting-the-australians-who-need-novavax-for-medical-reasons-20220121-p59q4n.html
  7. Read M. Health experts hope Novavax will sway vaccine hold-outs. Sydney: Financial Review; 2022. Available from: https://www.afr.com/politics/health-experts-hope-novavax-will-sway-vaccine-hold-outs-20220224-p59zgg
  8. Marchese AM, Beyhaghi H, Orenstein WA. With established safe and effective use, protein vaccines offer another choice against COVID-19. Vaccine. 2022;40(46):6567-9.  https://doi.org/10.1016/j.vaccine.2022.09.064  PMID: 36210248 
  9. Underwood E, Dunkle LM, Madhi SA, Gay CL, Heath PT, Kotloff KL, et al. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine. Expert Rev Vaccines. 2023;22(1):501-17.  https://doi.org/10.1080/14760584.2023.2218913  PMID: 37246757 
  10. Wilkinson B, Patel KS, Smith K, Walker R, Wang C, Greene AM, et al. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses. Vaccine. 2023;41(45):6762-73.  https://doi.org/10.1016/j.vaccine.2023.07.040  PMID: 37739888 
  11. European Medical Agency (EMA). Nuvaxovid product information. Annex 1. Summary of product characteristics. Amsterdam: EMA. [Accessed: 02Nov 2023. Available from: https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf
  12. Australian Government Department of Health - Therapeutic Goods Administration (TGA). Australian public assessment report for Nuvaxovid. Canberra: TGA; 2022.Available from: https://www.tga.gov.au/sites/default/files/2022-08/auspar-nuvaxovid-220726.pdf.
  13. United States Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee Meeting June 7, 2022. FDA briefing document Novavax COVID-19 vaccine. Maryland: FDA; 2022. Available from: https://www.fda.gov/media/158912/download
  14. Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, et al. Interim recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged ≥18 years - United States, July 2022. MMWR Morb Mortal Wkly Rep. 2022;71(31):988-92.  https://doi.org/10.15585/mmwr.mm7131a2  PMID: 35925807 
  15. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35(4):294-8. PMID: 22624490 
  16. Clothier HJ, Crawford NW, Russell M, Kelly H, Buttery JP. Evaluation of ‘SAEFVIC’, A pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf. 2017;40(6):483-95.  https://doi.org/10.1007/s40264-017-0520-7  PMID: 28342074 
  17. Australian Bureau of Statistics (ABS). 2021 census all persons QuickStats. Canberra: ABS; 2021. Available from: https://abs.gov.au/census/find-census-data/search-by-area
  18. Department of Health Western Australia. Western Australian vaccine safety surveillance – annual report 2021. Perth: Department of Health; 2021. Available from: https://www.health.wa.gov.au/~/media/Corp/Documents/Health-for/Immunisation/Western-Australia-Vaccine-Safety-Surveillance-Annual-Report-2021.pdf
  19. Government of Western Australia Department of Health. Public health act 2016. Sydney: Parliamentary Counsel's Office. [Accessed: 2 Nov 2023]. Available from: https://www.legislation.wa.gov.au/legislation/statutes.nsf/main_mrtitle_13791_homepage.html
  20. Council for International Organizations of Medical Sciences (CIOMS). Definition and application of terms for vaccine pharmacovigilance. Geneva: CIOMS; 2012. Available from: https://cdn.who.int/media/docs/default-source/pvg/global-vaccine-safety/cioms_report_wg_vaccine.pdf
  21. Brighton Collaboration. Brighton Collaboration case definitions. Decatur: The Task Force for Global Health. [Accessed: 2 Nov 2023]. Available from: https://brightoncollaboration.us/category/pubs-tools/case-definitions
  22. Australian Government Services Australia. Australian immunisation register. Forrest: Services Australia. [Accessed: 2 Nov 2023]. Available from: https://www.servicesaustralia.gov.au/australian-immunisation-register
  23. Alami A, Krewski D, Farhat N, Mattison D, Wilson K, Gravel CA, et al. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. BMJ Open. 2023;13(6):e065687.  https://doi.org/10.1136/bmjopen-2022-065687  PMID: 37339840 
  24. Therapeutic Goods Administration. COVID-19 vaccine weekly safety report - 23-06-2022. Canberra: Department of Health and Aged Care; 2022. Available from: https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-weekly-safety-report-23-06-2022#nuvaxovid-novavax-vaccine
  25. Duijster JW, Lieber T, Pacelli S, Van Balveren L, Ruijs LS, Raethke M, et al. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature. Front Immunol. 2023;14:1078736.  https://doi.org/10.3389/fimmu.2023.1078736  PMID: 36793715 
  26. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33(1):577-99.  https://doi.org/10.1146/annurev-cellbio-100616-060718  PMID: 28992436 
  27. Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021;39(25):3313-4.  https://doi.org/10.1016/j.vaccine.2021.04.066  PMID: 34020815 
  28. Heidari S, Palmer-Ross A, Goodman T. A systematic review of the sex and gender reporting in COVID-19 clinical trials. Vaccines (Basel). 2021;9(11):1322.  https://doi.org/10.3390/vaccines9111322  PMID: 34835253 
  29. Shetty AN, SepulvedaKattan G, Javed M, et al. Menstrual cycle changes increased following COVID-19 mRNA vaccination: Social media validation and self-controlled case series analysis. medRxiv. 2023;. https://doi.org/10.1101/2023.10.26.23297643 
  30. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410-22.  https://doi.org/10.1038/s41591-021-01630-0  PMID: 34907393 
  31. Kim S, Ko M, Heo Y, Lee YK, Kwon Y, Choi SK, et al. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over. Vaccine. 2023;41(35):5066-71.  https://doi.org/10.1016/j.vaccine.2023.06.077  PMID: 37422379 
  32. Kim HY, Cho JY, Yoon HJ, Choi YD, Ahn Y, Jeong MH, et al. A case report for acute myopericarditis after NVX-CoV2373 (Novavax®) COVID-19 vaccination. J Korean Med Sci. 2022;37(34):e265.  https://doi.org/10.3346/jkms.2022.37.e265  PMID: 36038960 
  33. Effler P. Clinician alert #65 – all clinicians. Perth: Department of Health. 2021. Available from: https://www.health.wa.gov.au/~/media/Corp/Documents/Health-for/Infectious-disease/COVID19/COVID19-Clinician-Alert-WA-65.pdf
  34. Laemmle-Ruff I, Lewis G, Clothier HJ, Dimaguila GL, Wolthuizen M, Buttery J, et al. Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline. Front Public Health. 2022;10:1053637.  https://doi.org/10.3389/fpubh.2022.1053637  PMID: 36408022 
  35. Black SB, Chandler RE, Edwards KM, Sturkenboom MCJM. Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future. Vaccine. 2023;41(25):3790-5.  https://doi.org/10.1016/j.vaccine.2023.04.055  PMID: 37198019 
  36. Victorian  Department  of  Health  COVID-19  writing  group. Population-based analysis of the epidemiological features of COVID-19 epidemics in Victoria, Australia, January 2020 - March 2021, and their suppression through comprehensive control strategies. Lancet Reg Health West Pac. 2021;17:100297.  https://doi.org/10.1016/j.lanwpc.2021.100297  PMID: 34723232 
  37. Phillips A, Jiang Y, Walsh D, Andrews N, Artama M, Clothier H, et al. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis. Vaccine. 2023;41(42):6227-38.  https://doi.org/10.1016/j.vaccine.2023.08.079  PMID: 37673715 
  38. Clothier HJ, Shetty AN, Mesfin Y, Mackie M, Pearce C, Buttery JP. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety. Vaccine. 2024;42(5):1108-15.  https://doi.org/10.1016/j.vaccine.2024.01.025  PMID: 38262811 
  39. Macías Saint-Gerons D, Ibarz MT, Castro JL, Forés-Martos J, Tabarés-Seisdedos R. Myopericarditis associated with the Novavax COVID-19 vaccine (NVX-CoV2373): a retrospective analysis of individual case safety reports from VigiBase. Drugs Real World Outcomes. 2023;10(2):263-70.  https://doi.org/10.1007/s40801-023-00355-5  PMID: 36788170 
  40. Ahmad S, Yuson C, Le A, Hissaria P. Myopericarditis following both BNT162b2 and NVX-CoV2373. Allergy Asthma Clin Immunol. 2022;18(1):109.  https://doi.org/10.1186/s13223-022-00750-7  PMID: 36564782 
  41. Shetty AN, Sepulveda Kattan G, Javed M, Pearce C, Clothier HJ, Buttery JP, et al. Menstrual cycle changes increased following COVID-19 mRNA vaccination: Social media validation and self-controlled case series analysis. MedRxiv [Preprint]. 2023; https://doi.org/10.1101/2023.10.26.23297643 
  42. Gianfredi V, Moretti M, Lopalco PL. Countering vaccine hesitancy through immunization information systems, a narrative review. Hum Vaccin Immunother. 2019;15(11):2508-26.  https://doi.org/10.1080/21645515.2019.1599675  PMID: 30932725 
  43. Danchin M, Buttery J. COVID-19 vaccine hesitancy: a unique set of challenges. Intern Med J. 2021;51(12):1987-9.  https://doi.org/10.1111/imj.15599  PMID: 34713544 
  44. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983;249(13):1743-5.  https://doi.org/10.1001/jama.1983.03330370053031  PMID: 6827763 
Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Hazel+J+Clothier&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Clothier Hazel J</a>, <a href="/search?value1=Claire+Parker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Parker Claire</a>, <a href="/search?value1=John+H+Mallard&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mallard John H</a>, <a href="/search?value1=Paul+Effler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Effler Paul</a>, <a href="/search?value1=Lauren+Bloomfield&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bloomfield Lauren</a>, <a href="/search?value1=Dale+Carcione&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Carcione Dale</a>, <a href="/search?value1=Jim+P+Buttery&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Buttery Jim P</a></span>. Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(50):pii=2400164. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.50.2400164" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.50.2400164</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 17 Mar 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 08 Aug 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.50.2400164
/content/10.2807/1560-7917.ES.2024.29.50.2400164
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error